Internal Costs. 12.2.1 Subject to Clauses 12.2.2 and 12.2.3 (Internal Costs), the Internal Costs incurred by each Council shall be borne by the Council providing that internal resource.
Internal Costs. (a) The Internal Costs incurred by each Council for a project in its own area shall be borne in the first instance by the Council providing that internal resource but may subsequently be included as costs within a Project Business Case.
Internal Costs. 12.2.1 Subject to Clause 12.2.2, the Internal Costs incurred by each Party (including the Accountable Body) shall be borne by the Party providing that internal resource.
Internal Costs. The Internal Costs incurred by each Council shall be borne in the first instance by the Council providing that internal resource. In the event that a Council is required to bear an Internal Cost which that Council views as excessive, the Council can make a request to the Joint Committee that the costs in question form part of the Annual Budget.
Internal Costs. (i) Material Costs, which means the prices paid to Third Parties for raw materials including intermediates and active compounds, excipients, components, packaging and labeling materials to the extent used in the manufacture and transportation of Product and purchased finished goods which are purchased from outside vendors as well as any freight and duty where applicable. Material Costs includes the quantity of the components included in the xxxx of material multiplied by the purchase price and the waste factor (i.e., scrap percentage) included in the xxxx of materials. It also includes the normal quality assurance sample quantity which is included in the xxxx of materials; and
Internal Costs. In addition, Development Costs shall include Out-of-Pocket Costs and direct and identifiable variable personnel costs of (w) manufacturing clinical supplies of Products, (x) process development for clinical and commercial scale manufacture of Products, including without limitation manufacturing process optimization in accordance with Section 6.12(h), (y) stability studies and (z) providing manufacturing transition support in accordance with Section 6.12.
Internal Costs. Abbott will initially provide funding for Neurocrine FTEs devoted to the conduct of the Transition Program in accordance with the Transition Plan, at a rate of […***…] per FTE per year (such rate will be prorated for any partial year), and provided such funding shall not exceed […***…] without Xxxxxx’x prior written permission. The contemplated allocation of Neurocrine FTEs devoted to the conduct of the Transition Program in accordance with the Transition Plan, as of the Effective Date, is […***…]. Neurocrine FTEs in […***…] will be allocated by the JDC in accordance with the Transition Plan and Section 6.1(c) from time to time based on the progress of the activities under the Transition Plan. Within […***…] days after the end of each Abbott Quarter after the Effective Date, Neurocrine will provide to Abbott an invoice setting forth the amount of funding for Neurocrine FTEs allocated to Transition Plan activities in such preceding Abbott Quarter as well as a FTE report for the preceding Abbott Quarter, which FTE report details the FTEs committed to the Transition Program by department and/or functional area, and a brief summary of the work performed (which summary may be limited to references to the reports to the JDC). Invoices will be payable by Abbott within […***…] days of receipt of the invoice.
Internal Costs. Except (i) [***], each Party shall bear its own internal costs incurred in connection with the Commercialization of each Joint Product in the applicable Profit Share Region unless otherwise agreed upon by the Parties in writing, it being the intention of the Parties that over time and over the course of the conduct of the applicable Commercialization Plans, each Party shall have contributed approximately equal internal resources to the conduct of such Commercialization activities as it does in relation to the amount of Operating Profits and Operating Losses it shares with respect to such Joint Product (i.e., 50% or 30% or 70%, as the case may be). In the event a Party is of the opinion that there is a material discrepancy between the allocation of internal costs between the Parties with respect to their joint Commercialization activities and their Operating Profit and Operating Loss allocation, the Parties shall discuss in good faith a mechanism to rebalance the allocation of such internal costs between the Parties to achieve approximately an appropriate ratio; it being understood, however, that the Parties shall not be required to track internal costs or time in connection with their Commercialization activities unless the Parties otherwise agree. Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission.
Internal Costs. Abbott will provide funding for Neurocrine FTEs devoted to the conduct of the Collaborative Development Program in accordance with the Collaborative Development Plan at a rate of […***…] per year (such rate will be prorated for any partial year), in an amount equal to […***…] over the term of the Collaborative Development Program (the “Neurocrine FTE Funding Commitment”). The Neurocrine FTE Funding Commitment will not exceed […***…] without Xxxxxx’x prior written permission.
Internal Costs. While the Parties agree to share Development Costs incurred by each Party for joint Development in accordance with this Section 5.5, each Party shall bear its own internal costs incurred in connection with the conduct of joint Development activities unless otherwise agreed upon by the Parties in writing, it being the intention of the Parties that over time and over the course of the conduct of the Joint Plan(s), each Party shall have contributed approximately equal internal resources to the conduct of such Development activities as it does in relation to the amount of Development Costs it has been allocated to fund (i.e., 50% or 30% or 70%, as the case may be). In the event a Party is of the opinion that there is a material discrepancy between the allocation of internal costs between the Parties with respect to their joint Development activities and their Development Cost allocation, the Parties shall discuss in good faith a mechanism to rebalance the allocation of such internal costs between the Parties to achieve approximately an appropriate ratio; it being understood, however, that the Parties shall not be required to track internal costs or time in connection with their Development activities unless the Parties otherwise agree.
